Ahead of Supply Side West 2023, Sirio has three pieces of news with two new product announcement and in bigger news a first gummy manufacturing line in USA. The latter is expected to be ready for production at the end of October 2023.
The new gummy production line will open at Best Formulations, its US based manufacturing facility. Once open this will provide the global CDMO with local manufacturing in three continents. The gummy development includes a dedicated R&D lab, automated lines, packaging and will specialise in the delivery of custom formulations.
In Europe, the nutraceutical CDMO has launched five seasonal products including three bioactive gummies for ‘cough and cold’, ‘oral care’ and ‘Urinary Tract Infections’ (UTI) and two softgels for menopause and eye health targeting customers who look to innovate in the consumer health space. The new formulations are designed to meet the rising demand of consumers for products with more natural actives to help OTC customers tap consumer trends.
A state-of-the-art Automated Starch-free Gummy Line at Best Formulations – purchased from Tanis OTC – is able to produce a variety of gummies including gelatin-based, pectin-based, and gelatin-pectin combinations, with both plant-base and sugar free options available.
“We are thrilled to introduce our advanced gummy manufacturing capabilities,” said Edward Shneyvas, VP of R&D, Innovation and Business Development at Best Formulations. “With our expertise in delivering tailored solutions, we remain committed to driving innovation and delighting our customers.”